AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.

Trial Details

NCT ID
NCT06951503
Phase
PHASE3
Sponsor
Akeso
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • AK112
  • Oxaliplatin
  • Irinotecan
  • Leucovorin and 5-FU
  • Bevacizumab
Locations (sample)
  • Guanzhou, Guangdong, China|23.06828,113.37117
  • Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

  • Signed informed consent.
  • Age ≥ 18 years and ≤ 75 years.
  • ECOG status of 0 or 1.
  • Estimated survival ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →